Skip to main navigation Skip to search Skip to main content

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): A report from the Children's Oncology Group

  • Phoenix A. Ho
  • , Todd A. Alonzo
  • , Robert B. Gerbing
  • , Jessica Pollard
  • , Derek L. Stirewalt
  • , Craig Hurwitz
  • , Nyla A. Heerema
  • , Betsy Hirsch
  • , Susana C. Raimondi
  • , Beverly Lange
  • , Janet L. Franklin
  • , Jerald P. Radich
  • , Soheil Meshinchi

Research output: Contribution to journal › Article › peer-review

Abstract

CEBPA mutations have been associated with improved outcome in adult acute myeloid leukemia (AML). We evaluated the prevalence and prognostic signifi-cance of CEBPA mutations in 847 children with AML treated on 3 consecutive pediatric trials. Two types of CEBPA mutations - N-terminal truncating mutations and in-frame bZip-domain mutations - were detected in 38 (4.5%) of 847 patients tested; 31 (82%) of 38 patients with mutations harbored both mutation types. Mutation status was correlated with laboratory and clinical characteristics and clinical outcome. CEBPA mutations were significantly more common in older patients, patients with FAB M1 or M2, and patients with normal karyotype. Mutations did not occur in patients with either favorable or unfavorable cytogenetics. Actuarial eventfree survival at 5 years was 70% versus 38% (P = .015) with a cumulative incidence of relapse from complete remission of 13% versus 44% (P = .007) for those with and without CEBPA mutations. The presence of CEBPA mutations was an independent prognostic factor for improved outcome (HR = 0.24, P = .047). As CEBPA mutations are associated with lower relapse rate and improved survival, CEBPA mutation analysis needs to be incorporated into initial screening for risk identification and therapy allocation at diagnosis. The clinical trials in this study are registered at http://www.clinicaltrials. gov under NCT00002798 and NCT00070174.

Original languageEnglish (US)
Pages (from-to)6558-6566
Number of pages9
JournalBlood
Volume113
Issue number26
DOIs
StatePublished - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): A report from the Children's Oncology Group'. Together they form a unique fingerprint.

Cite this